This Phase 2 clinical trial (ViDAS-2) will determine if daily oral vitamin D for children with sickle- cell disease can reduce the risk of respiratory complications, the leading cause of morbidity and mortality. Our previous ViDAS-1 clinical trial provided evidence that monthly bolus oral vitamin D3 supplementation in children with sickle cell disease reduced the annual rate of respiratory complications by more than 50% (P=0.0005) but only after a year of treatment and with no significant difference between vitamin D3 given as standard- (12,000 IU/mo) or high- (100,000 IU/mo) dose therapy. The scientific premise of the proposed clinical trial is that increased circulating concentrations of vitamin D3, the parent compound, are needed for the anti-infective and immunomodulatory effects of supplementation. With monthly bolus oral vitamin D3, circulating vitamin D3 is cleared from the circulation within days. In the earlier ViDAS-1 clinical trial of monthly bolus oral vitamin D3, neither the standard- nor high-dose treatments would produce sustained increases in circulating vitamin D3, potentially explaining both the uniformity of response to the two treatments and the delay in reducing the rates of respiratory events. With monthly bolus oral dosing, vitamin D3 slowly accumulates in adipose tissue and would only gradually increase circulating vitamin D3 concentrations. Our hypothesis is that daily oral vitamin D3 will rapidly increase circulating vitamin D3 and reduce the rate of respiratory complications by 50% or more within the first year of treatment. We propose a 2-year controlled, double-masked, randomized Phase 2 clinical trial comparing the efficacy in reducing the rate of respiratory events in sickle-cell disease of daily oral vitamin D3 (3,333 IU/d) with monthly bolus oral vitamin D3, (100,000 IU/mo) as a control. Baseline concentrations of 25-hydroxyvitamin D in our population (mean ~14 ng/mL) guide the choice of the high-dose daily treatment and are too low to permit inclusion of a placebo control. This Phase 2 clinical trial has three specific aims: (1) to determine whether daily oral vitamin D3 (3,333 IU/d) given to children and adolescents with sickle-cell disease, compared to monthly bolus oral vitamin D3, (100,000 IU/mo) will more rapidly reduce the rate of respiratory events, defined as respiratory infections, exacerbations of asthma, and episodes of the acute chest syndrome; (2) to evaluate the effects of daily oral vitamin D3 on pulmonary function; and (3) to examine the effects of daily oral vitamin D3 on immune function, using biomarkers of systemic inflammation and of T-cell effector and regulatory function..

Public Health Relevance

This Phase 2 clinical trial (ViDAS-2) will determine if daily oral vitamin D for children with sickle- cell disease can reduce the risk of respiratory complications, the leading cause of morbidity and mortality. The results could show that daily oral vitamin D is more effective than monthly bolus dosing in producing the anti-infective and immunomodulatory effects of supplementation. Daily oral vitamin D could offer a simple, low-cost intervention to help avert serious respiratory complications in sickle-cell disease that could lead to important reductions in morbidity and death in children with sickling disorders.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Project (R01)
Project #
5R01FD006372-02
Application #
10004019
Study Section
Special Emphasis Panel (ZFD1)
Program Officer
Russell, Karen
Project Start
2019-09-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
2
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032